ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМПymj-2018Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHВзаимосвязь полиморфизма гена CYP2E1 и переносимости химиотерапии рака яичниковRelationship of CYP2E1 gene polymorphism and tolerability of ovarian cancer chemotherapyИвановаФ. Г.IvanovaF. G.

Иванова Феодосия Гаврильевна – к.м.н., зав. лаб.;

зав. отд. химиотерапии;

гл. внештат. Онколог

ЧердынцеваН. В.CherdyntsevaN. V.

Чердынцева Надежда Викторовна – д.б.н., проф., зам. директора по науке

nii@oncology.tomsk.ruХрунинА. В.KhruninA. V.

Хрунин Андрей Владимирович – к.м.н., с.н.с.

khrunin@img.ras.ruГорбуноваВ. А.GorbunovaV. A.

Горбунова Вера Андреевна – д.м.н., проф., руковод. отд. Химиотерапии

ЯНЦ КМП СО РАМН; ГБУ ЯРОД; МЗ РС(Я)Russian FederationФБГУ НИИ онкологии СО РАМНRussian FederationФБГУ Институт молекулярной генетики РАНRussian FederationФБГУ РОНЦ им. Н.Н. Блохина РАМНRussian Federation201212102025043537Copyright © Иванова Ф.Г., Чердынцева Н.В., Хрунин А.В., Горбунова В.А., 20252025Иванова Ф.Г., Чердынцева Н.В., Хрунин А.В., Горбунова В.А.Ivanova F.G., Cherdyntseva N.V., Khrunin A.V., Gorbunova V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/2018

Проведен анализ ответа на химиотерапию и полиморфизма гена CYP2E1 в группах больных раком яичников и здоровых женщин якутской этнической группы. Выявлены существенные различия по частоте встречаемости аллеля CYP2E1*1D (вставка 96 п.о. в промоторной области гена). Более высокое его содержание отмечено в группе здоровых женщин.

The response to chemotherapy and CYP2E1 polymorphism gene in groups of ovarian cancer patients and healthy women of Yakut ethnic group was analyzed. Significant differences in the frequency of allele CYP2E1 * 1D (96 bp insertion in the promoter region of the gene) were revealed. The higher content was observed in the group of healthy women.

ДНК полиморфизмCYP2E1химиотерапиярак яичниковякутыDNA polymorphismsCYP2E1chemotherapyovarian cancerYakutsReferencesМолекулярно-генетические особенности прогрессии и ответа на терапию злокачественных новообразований: этнические аспекты / Н.В. Чердынцева, Ф.Г Иванова, Н.В. Литвяков [и др.] // Медицинская генетика.- 2011. - №10. - С.28-36.Molecular-genetic features of progression and response to therapy of malignant tumors: ethnical aspects / N.V. Cherduntseva, F.G. Ivanova, N.V.Litvyakov [et al.] //Medical genetics. - 2011, №10. - P.28-36.Bolt H.M. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine / H.M. Bolt, P.H. Roos, R. Thier // Int Arch Occup Environ Health. - 2003. V. 76, № 3. - P. 174-85.Bolt H.M. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine / H.M. Bolt, P.H. Roos, R. Thier // Int Arch Occup Environ Health. - 2003. V. 76, № 3. - P. 174-85.Caro A.A. Oxidative stress, toxicology, and pharmacology of CYP2E1 /A.A. Caro, A.I.Cederbaum// Annu Rev Pharmacol Toxicol. – 2004. – V. 44. – P. 27-42.Caro A.A. Oxidative stress, toxicology, and pharmacology of CYP2E1 /A.A. Caro, A.I.Cederbaum// Annu Rev Pharmacol Toxicol. – 2004. – V. 44. – P. 27-42.Danko I.M. Association of CYP2E1 gene polymorphism with predisposition to cancer development / I.M. Danko, N.A. Chaschin. // Exp Oncol. – 2005. – V. 27, № 4. – P. 248-56.Danko I.M. Association of CYP2E1 gene polymorphism with predisposition to cancer development / I.M. Danko, N.A. Chaschin. // Exp Oncol. – 2005. – V. 27, № 4. – P. 248-56.Fritsche E. Localization, sequence analysis, and ethnic distribution of a 96-bp insertion in the promoter of the human CYP2E1 gene / E. Fritsche, G.S. Pittman, D.A. Bell.// Mutation Research Genomics. - 2000. - V. 432. - P. 1–5.Fritsche E. Localization, sequence analysis, and ethnic distribution of a 96-bp insertion in the promoter of the human CYP2E1 gene / E. Fritsche, G.S. Pittman, D.A. Bell.// Mutation Research Genomics. - 2000. - V. 432. - P. 1–5.Gemma S. Individual susceptibility and alcohol effects:biochemical and genetic aspects /S. Gemma, S. Vichi, E. Testai // Ann Ist SuperSanita. – 2006. – V. 42, № 1. – P. 8-16.Gemma S. Individual susceptibility and alcohol effects:biochemical and genetic aspects /S. Gemma, S. Vichi, E. Testai // Ann Ist SuperSanita. – 2006. – V. 42, № 1. – P. 8-16.Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients / A.V. Khrunin, A.Moisseev, V Gorbunova [et al.] //Pharmacogenomics J. - 2010. - V. 10, № 1. - P. 54-61.Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients / A.V. Khrunin, A.Moisseev, V Gorbunova [et al.] //Pharmacogenomics J. - 2010. - V. 10, № 1. - P. 54-61.Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity / P. Neafsey, G. Ginsberg, D. Hattis [et al.] // J Toxicol Environ Health B Crit Rev. - 2009. - V. 12, № 5-6. - P. 362-88.Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity / P. Neafsey, G. Ginsberg, D. Hattis [et al.] // J Toxicol Environ Health B Crit Rev. - 2009. - V. 12, № 5-6. - P. 362-88.Genetic polymorphisms of CYP2E1 and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study / M. Morita, L. Le Marchand, Kono S. [et al.]// Cancer Epidemiol Biomarkers Prev. - 2009. - V. 18, № 1. - P. 235-41.Genetic polymorphisms of CYP2E1 and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study / M. Morita, L. Le Marchand, Kono S. [et al.]// Cancer Epidemiol Biomarkers Prev. - 2009. - V. 18, № 1. - P. 235-41.Liu K. Power Marker: an integrated analysis environment for genetic marker analysis / K. Liu, S.V. Muse // Bioinformatics. - 2005. - V. 21, № 9. - P. 2128-9.Liu K. Power Marker: an integrated analysis environment for genetic marker analysis / K. Liu, S.V. Muse // Bioinformatics. - 2005. - V. 21, № 9. - P. 2128-9.Marchand L.L. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone./ L.L. Marchand, G.R. Wilkinson, L.R. Wilkens.// Cancer Epidemiol Biomarkers Prev. - 1999. - V. 8, № 6. - P. 495-500.Marchand L.L. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone./ L.L. Marchand, G.R. Wilkinson, L.R. Wilkens.// Cancer Epidemiol Biomarkers Prev. - 1999. - V. 8, № 6. - P. 495-500.Milligan B.G. Total DNA isolation / B.G. Milligan // Molecular genetic analysis of populations / Ed. by A.R. Hoelzel. - London: Oxford University Press, 1998. - P. 29-60.Milligan B.G. Total DNA isolation / B.G. Milligan // Molecular genetic analysis of populations / Ed. by A.R. Hoelzel. - London: Oxford University Press, 1998. - P. 29-60.Role of the genetic polymorphisms in the 5'-flanking region for transcriptional regulation of the human CYP2E1 gene / T. Uchimoto, S. Itoga, M. Nezu, M. Sunaga [et al.] // Alcohol Clin Exp Res. - 2007. - V. 31, № 1 Suppl. - P. S36-42.Role of the genetic polymorphisms in the 5'-flanking region for transcriptional regulation of the human CYP2E1 gene / T. Uchimoto, S. Itoga, M. Nezu, M. Sunaga [et al.] // Alcohol Clin Exp Res. - 2007. - V. 31, № 1 Suppl. - P. S36-42.Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer / S. Itoga, F. Nomura, Y. Makino [et al.] // Alcohol Clin Exp Res. - 2002. - V. 26, № 8 Suppl. - P. 15S-19S.Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer / S. Itoga, F. Nomura, Y. Makino [et al.] // Alcohol Clin Exp Res. - 2002. - V. 26, № 8 Suppl. - P. 15S-19S.Transcriptional activity of the tandem repeat polymorphism in the 5'-flanking region of the human CYP2E1 gene / F. Nomura, S. Itoga, T. Uchimoto [et al.] // Alcohol Clin Exp Res. - 2003. - V. 27, № 8 Suppl. - P. 42S-46S.Transcriptional activity of the tandem repeat polymorphism in the 5'-flanking region of the human CYP2E1 gene / F. Nomura, S. Itoga, T. Uchimoto [et al.] // Alcohol Clin Exp Res. - 2003. - V. 27, № 8 Suppl. - P. 42S-46S.

The authors declare that there are no conflicts of interest present.